ARTES attends European Animal Health Investment Forum

ARTES will head for London’s elite May­fair dis­trict in Feb­ru­ary to take part in the ‘Drag­ons Den’ of vet­eri­nary med­i­cine, the Euro­pean Ani­mal Health Invest­ment Forum.

This will be ARTES’ first par­tic­i­pa­tion in the high pres­tige invest­ment net­work­ing event.

ARTES will be rep­re­sent­ed by its Man­ag­ing Direc­tor, Dr. Michael Pio­ntek, who will be talk­ing in par­tic­u­lar about the devel­op­ment of its inno­v­a­tive pro­pri­etary vac­cine devel­op­ment plat­form, METAVAX®.

METAVAX®advantages

METAVAX® gen­er­ates vac­cines based on the WHO-rec­om­mend­ed yeast organ­ism Hansenu­la poly­mor­pha.

ARTES Biotech­nol­o­gy also has exper­tise in human and ani­mal vac­cine devel­op­ment and is col­lab­o­rat­ing with ani­mal health leader Boehringer Ingel­heim to devel­op  a vac­cine based on Hansenu­la poly­mor­pha expres­sion, com­bined with the METAVAX® plat­form

Self-adjuvanting vaccines

We look for­ward to attend­ing the Euro­pean Ani­mal Health Invest­ment Forum for the oppor­tu­ni­ty to net­work with CEOs, busi­ness devel­op­ers and sci­en­tists from vet­eri­nary phar­ma­ceu­ti­cal com­pa­nies inter­est­ed in devel­op­ment of high­ly immuno­genic vac­cines,” com­ment­ed Dr. Pio­ntek.

This is a great oppor­tu­ni­ty to find new con­tacts, refresh old ones and show how we have devel­oped an eco­nom­i­cal approach for low-cost mass pro­duc­tion of safe, effec­tive and self-adju­vant­i­ng vac­cines,” said Dr. Pio­ntek.

ARTES will also use the meet­ing to share knowl­edge about its VLP tech­nol­o­gy for anti­gen pre­sen­ta­tion and oth­er vac­cine tech­nolo­gies.  It will also exchange infor­ma­tion on its spe­cial­ist cell lines and process devel­op­ment for bio-phar­ma­ceu­ti­cal prod­ucts.

Meet us at the Ani­mal Health Invest­ment in Lon­don, 22nd and 23rd Feb­ru­ary, at the Mil­len­ni­um Lon­don May­fair Hotel or con­tact us pre­vi­ous­ly for a per­son­al meet­ing! We look for­ward to meet­ing you!